Listen to our experts providing a brief summary on key data supporting the use of immunotherapy in lung cancer, head & neck cancer, and urologic malignancies, as well as the use of immunotherapy beyond current established indications.
Oct 25, 2018
Oct 25, 2019
Mario Colombo, PhDFondazione IRCCS - Istituto Nazionale dei Tumori
Giuseppe Curigliano, MD, PhDEuropean Institute of Oncology
University of Milan
Jean-Pascal Machiels, MD, PhDCliniques universitaires Saint-Luc
Université catholique de Louvain
David Planchard, MD, PhDGustave Roussy
David I. Quinn, MBBS, PhD, FRACP, FACPUniversity of Southern California
Norris Cancer Hospital
Los Angeles, California, United States
Patient Selection for Immunotherapy: Making Sense of Current and Emerging Biomarkers
Mario Colombo, PhD
Coping With the Whirlwind of Change in Lung Cancer Treatment
David Planchard, MD, PhD
The Emerging Role for Immunotherapy in Head & Neck Cancer
Jean-Pascal Machiels, MD, PhD
The Expanding Role of Immunotherapy for Urologic Malignancies
David I. Quinn, MBBS, PhD, FRACP, FACP
Extending Immunotherapy Beyond Established Indications
Giuseppe Curigliano, MD, PhD
Giuseppe Curigliano, MD, PhD
This educational activity is intended for medical oncologists and other healthcare professionals interested in immunotherapy approaches for solid tumors.
After successful completion of this educational activity, participants should be able to:
- Describe the clinical application of checkpoint inhibitors to the treatment pathways for lung, bladder, and head & neck cancer
- Discuss the current and emerging data with checkpoint inhibition in prostate, breast, ovarian, and colorectal cancer
- Apply the use of biomarkers to guide treatment selection
- Incorporate multidisciplinary strategies to monitor and manage immune-related adverse events
This educational activity is supported by a grant from AstraZeneca Pharmaceuticals LP.
Enduring Materials From a Certified Activity
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Colombo has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Curigliano has disclosed that he has received consulting fees and honoraria for promotional speakers’ bureaus from Pfizer and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Machiels has disclosed that he is a member on the advisory board of Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Debiopharm Group, Innate Pharma, Merck Serono, and Merck Sharp & Dohme Corp. He is also a speaker and teacher for Merck Sharp & Dohme Corp and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Planchard has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme Corp, Novartis, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Quinn has disclosed that he has received board membership fees and consulting fees from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Dendreon, EMD Serono, Exelixis, Genentech/Roche, Janssen, Merck Sharp & Dohme Corp, Novartis, Pfizer, and Sanofi. He is also independently contracted by Genentech, GlaxoSmithKline, Millennium, and Sanofi. He has disclosed membership on advisory committee or review panel for Eisai. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.